At insitro, we are combining human biology and machine learning to discover and develop new therapeutics. The heart of our strategy is to produce large data sets that will drive machine learning and yield key biological insights. This strategy requires a seamless, robust, and effective operation that simultaneously spans multiple projects, some partnered and some in-house.
Reporting to the Controller / VP, Finance, we are seeking a dynamic, detail oriented and versatile Senior Manager, Financial Reporting & Technical Accounting to join our growing Accounting and Finance Team. In this hands on role, you will be responsible for the preparation of all financial reporting and technical accounting memos and analysis. Further, you will be responsible for all stock administration, stock based compensation reporting, revenue recognition and other higher risk month-end close related activity. In addition, you will lead and implement process controls, compliance and maintenance of all accounting policies. A successful candidate has a strong understanding of US GAAP and reporting and stays current with recent accounting pronouncements. This role will regularly interact with Legal, HR, Business Development, Program Management, and various members of our Leadership Team.
Your primary duties will be:
You will be joining an exciting biotech startup that has long-term stability due to significant funding, yet is very much in formation. A lot can change in this early and exciting phase, providing many opportunities for significant impact across several functions and disciplines. You will work closely with a very talented team, learn a broad range of skills, and help shape insitro’s culture, strategic direction, and outcomes. Join us in leading the way to better medicines through predictive models by integrating machine learning and biology at scale.
Benefits at insitro
insitro is a data-driven drug discovery and development company using machine learning and high-throughput biology to transform the way that drugs are discovered and delivered to patients. The company is applying state-of-the-art technologies from bioengineering to create massive data sets that enable the power of modern machine learning methods to be brought to bear on key bottlenecks in pharmaceutical R&D. The resulting predictive models are used to accelerate target selection, to design and develop effective therapeutics, and to inform clinical strategy. insitro was launched in 2018 with a Series A of $100M funded by top investors including a16z, Arch Venture Partners, Foresite Capital, GV, and Third Rock Ventures. In 2019 the company announced a collaboration with Gilead Sciences in the area of NASH and, in mid 2020, announced a Series B financing of $143M including current investors and new investors Canada Pension Plan Investment Board (CPP Investments), T. Rowe Price, BlackRock, Casdin Capital and other leading investors. The company is located in South San Francisco, CA. For more information about insitro, please visit the company’s website at www.insitro.com.
Your application was submitted successfully.